Evaluating the Use of Large-dose, Extended Interval Vancomycin Intravenous Administration for Skin and Soft Tissue Infections

• Status: Completed
• Trial end date: 2010-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Our hypothesis is that large-dose, extended-interval vancomycin (30 mg/kg IV q24h) administration provides non-inferior clinical efficacy and microbiological efficacy to standard vancomycin (15 mg/kg IV q12h) administration for skin and soft tissue infections in an outpatient setting.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fraser Health
• Treatments: Vancomycin

Criteria

Inclusion Criteria:

• Age 19 to 70 years

• Weight 40 - 80 kg

• Suspected or confirmed skin or soft tissue infection for which vancomycin is indicated

• Subject referred to or admitted into OPAT by an Infectious Disease Specialist or Emergency Physician

• Subject able to provide informed consent

Exclusion Criteria:

• Known history of allergy to vancomycin

• Pregnancy

• Granulocytopenia (< 1x109/L)

• Renal impairment (serum creatinine > 177 µmol/L or eGFR < 50 mL/min)

• Known history of vestibular disease or hearing loss

• Subjects treated with vancomycin within the previous month

• Subjects who have received more than 24 hours of vancomycin

• Subjects receiving other antimicrobials that cover MRSA (e.g. cotrimoxazole, rifampin, linezolid)